Loading institutional data...
Loading institutional data...
Institutional distribution: ownership decreased -1.28% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $16.25 today, the market must believe free cash flow compounds 10.6%/yr for a decade (off $21M normalized FCF).
2-stage DCF · 0.03B shares · net debt -$43M
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $6M buybacks = $6M returned on $21M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 2%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Interest last disclosed in FY2017 (no longer broken out).
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85.2M 100.0% | $37.2M 100.0% | $2.1M 100.0% | $2.7M 100.0% | $3.6M 100.0% | — | — | — | $2.7M 100.0% | $2.0M 100.0% |
| Cost of Revenue | $11.8M 13.8% | $6.2M 16.6% | $635K 30.8% | $686K 25.2% | $671K 18.9% | $640K | $719K | $1.0M | $701K 25.8% | $550K 27.6% |
| Gross Profit | $73.4M 86.2% | $31.0M 83.4% | $1.4M 69.2% | $2.0M 74.8% | $2.9M 81.1% | $1.0M | $861K | $2.4M | $2.0M 74.2% | $1.4M 72.4% |
| Research & Development | $29.2M 34.3% | $13.9M 37.3% | $17.5M 847.6% | $18.6M 683.4% | $13.8M 387.6% | $11.2M | $9.5M | $19.6M | $10.5M 386.6% | $8.4M 424.1% |
| Selling, General & Admin | $43.5M 51.1% | $29.6M 79.4% | $22.1M 1070.7% | $17.3M 636.4% | $13.6M 383.6% | $11.1M | $11.3M | $9.8M | $9.7M 356.7% | $9.4M 473.6% |
| Total Operating Expenses | $72.8M 85.4% | $43.4M 116.7% | $39.6M 1918.3% | $35.9M 1319.8% | $27.4M 771.2% | $22.3M | $20.8M | $29.5M | $20.2M 743.2% | $17.9M 897.7% |
| Operating Income | $660K 0.8% | -$12.4M -33.4% | -$38.2M -1849.0% | -$33.9M -1245.1% | -$24.5M -690.0% | -$21.3M | -$19.9M | -$27.1M | -$18.2M -669.1% | -$16.4M -825.3% |
| Interest Expense | — | — | — | — | — | — | — | — | $21.7M 799.4% | $14.3M 719.3% |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | $17K 0.9% |
| Other Income (Expense), net | -$70K -0.1% | -$30K -0.1% | -$59K -2.9% | $30K 1.1% | $68K 1.9% | $154K | $2K | $51K | -$41K -1.5% | $17K 0.9% |
| Pretax Income | $3.5M 4.1% | -$26.4M -70.9% | -$47.7M -2308.9% | -$36.5M -1342.7% | -$25.6M -721.5% | -$24.2M | -$8.9M | -$19.2M | -$45.1M -1661.8% | -$18.0M -902.1% |
| Income Tax Expense | $810K 1.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 | $0 | $0 | $0 0.0% | $0 0.0% |
| Net Income | $2.7M 3.2% | -$26.4M -70.9% | -$47.7M -2308.9% | -$36.5M -1342.7% | -$25.6M -721.5% | -$24.2M | -$8.9M | -$19.2M | -$45.1M -1661.8% | -$18.0M -902.2% |
| Per Share | ||||||||||
| EPS (Basic) | $0.08 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | — |
| EPS (Diluted) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | — |
| Weighted Avg Shares (Basic) | 35.8M | 28.5M | 16.2M | 8.9M | 7.1M | 2.9M | 26K | 26.7M | 14K | — |
| Weighted Avg Shares (Diluted) | 39.9M | 28.5M | 16.2M | 8.9M | 7.1M | 2.9M | 26K | 26.7M | 14K | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 8-yr range · 30th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 8-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | — | — | 18.9 | 25.2 | 30.8 | 16.6 | 13.8 |
| Gross Profit | — | — | — | 81.1 | 74.8 | 69.2 | 83.4 | 86.2 |
| R&D | — | — | — | 387.6 | 683.4 | 847.6 | 37.3 | 34.3 |
| SG&A | — | — | — | 383.6 | 636.4 | 1070.7 | 79.4 | 51.1 |
| Operating Income | — | — | — | -690.0 | -1245.1 | -1849.0 | -33.4 | 0.8 |
| Income Tax | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 |
| Net Income | — | — | — | -721.5 | -1342.7 | -2308.9 | -70.9 | 3.2 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on DCTH: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| DCTH | $564M | 232.1× | 579.4× | 6.6× | 129% | 86.2% | 3.2% | 2.4% | 2.4% | — | 120 |
Peers = companies sharing DCTH's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.